



Transderm Scop® (scopolamine) – First-time Generic

- On July 31, 2017, [Perrigo announced](#) the launch of its [AB-rated](#) generic equivalent to GlaxoSmithKline's [Transderm Scop® \(scopolamine\)](#) transdermal patch, indicated in adults for the prevention of nausea and vomiting associated with motion sickness, and the prevention of nausea and vomiting associated with recovery from anesthesia and/or opiate analgesia and surgery.
- The annual U.S. market sales for Transderm Scop were approximately \$158 million in the 12 months ending in May 2017.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.